Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kwang-Soo Kim
Mclean Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
NurrON Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Kim is a co-founder of NurrON Pharmaceuticals and has founder’s equity in the company. The company has two potential translational approaches. The first is related to the development of the personalized cell therapy being studied in this R01 grant. The second approach is focused on drug development using Nurr1 as a target. The results of this research grant on personalized cell therapy could be beneficial to NurrON’s efforts in this area. Based on the magnitude of Dr. Kim’s financial interest and the close connection between the company's interests and the research, the Committee on Outside Activities (COA) review panel determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Human iPSC-based personalized cell therapy of PD
The 'induced pluripotent stem cell (iPSC)' technology is a promising method that can revolutionize customized cell-based therapies of intractable human diseases such as PD. To realize the potential of using iPSCs in personalized cell-based therapy for PD, we propose to establish and characterize clinically viable iPSC lines by our novel reprogramming methods, to optimize their differentiation and purification of midbrain dopamine cells, and to test their functionality in rodent and primate models. This proposal will provide important stepping-stones for realistic development of a personalized cell-based therapy of PD and will lead to a new generation of cell replacement therapy of PD.
Filed on August 09, 2016.
Tell us what you know about Kwang-Soo Kim's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.